REG - BiVictriX Therapcts. - Last Day of Dealings

Bivictrix TherapeuticsAnnouncement

10/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240910:nRSJ4930Da&default-theme=true

RNS Number : 4930D  BiVictriX Therapeutics PLC  10 September 2024

BiVictriX Therapeutics plc

 

("BiVictriX", "BiVictriX Therapeutics" or the "Company")

 

Last Day of Dealings

 

Alderley Park, 10 September 2024 - BiVictriX (AIM: BVX), a drug discovery and
development company applying an innovative, proprietary approach to develop a
new class of highly selective, next generation cancer therapeutics, bispecific
antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency,
whilst reducing treatment-related toxicities, today provides a further update
with regards to the cancellation of admission of the Company's ordinary shares
to trading on AIM (the "Cancellation"), as originally announced on 12 August
2024, and as approved by shareholders at the general meeting held on 29 August
2024.

 

Shareholders are reminded that the last day of trading in the Ordinary Shares
on AIM is today, 10 September 2024, and Cancellation will become effective at
7:00 a.m. on 11 September 2024. Following Cancellation, the Company will
re-register as a private company under the name BiVictriX Therapeutics
Limited.

 

As previously announced, the Company has engaged JP Jenkins
(https://jpjenkins.com (https://jpjenkins.com/) ), a firm Authorised and
Regulated by the Financial Conduct Authority (FRN 950991), to operate a
matched bargain facility for the trading of ordinary shares. This facility
will allow existing shareholders of the Company and new investors to trade
ordinary shares by matching buy and sell orders. Further details can be found
on the Company's website www.bivictrix.com (http://www.bivictrix.com/) . The
JP Jenkins facility will be effective for a minimum of six months from 11
September 2024. Investors may wish to register on https://jpjenkins.com
(https://jpjenkins.com/) and add BiVictriX Therapeutics Limited to their
'Watchlist' to continue to receive auction/price information and updates.

 

Shareholders will continue to be able to hold their shares in uncertificated
form (i.e. in CREST) and should check with their existing stockbroker whether
they are willing or able to trade in unquoted shares. Shareholders wishing to
trade shares through JP Jenkins must do so through a stockbroker. A
comprehensive list of stockbrokers who have signed up to access the JP Jenkins
platform is available on request.

 

Following Cancellation, shareholders are encouraged to sign up to the
Company's email news alerts via the BiVictriX website or to follow the Company
on LinkedIn to stay updated on its continued development of next generation
cancer therapeutics as a private company.

 

Further details regarding the cancellation and re-registration are set out in
the circular sent to shareholders dated 12 August 2024. A copy of the circular
is available on the Company's website www.bivictrix.com
(http://www.bivictrix.com/) .

 

Following Cancellation, SP Angel Corporate Finance LLP will cease to act as
nominated adviser and corporate broker to the Company, and Panmure Liberum
Limited will cease to act as corporate broker to the Company.

 

Capitalised terms used but not defined in this announcement shall have the
same meaning given to such terms in the Circular.

 

**ENDS**

 

For more information, please contact:

 BiVictriX Therapeutics plc

 Tiffany Thorn, Chief Executive Officer                         Email: info@bivictrix.com

 Michael Kauffman, Non-Executive Chairman

 SP Angel Corporate Finance LLP (NOMAD and Broker)
 David Hignell, Caroline Rowe (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales and Broking)                Tel: +44 (0) 20 3470 0470

 Panmure Liberum Limited (Joint Broker)
 Emma Earl, Freddy Crossley, Mark Rogers, Rupert Dearden

                                                               Tel: +44 (0) 20 3100 2000

 ICR Consilium

 Namrata Taak, Lucy Featherstone, Max Bennett, Emmalee Hoppe   Tel: +44 (0) 20 3709 5700

                                                               Email: Bivictrix@consilium-comms.com

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical
experience and its proprietary discovery engine to advance a new class of
highly cancer-selective, next-generation precision cancer therapies in one of
the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni®
Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially
improved cancer-selectivity and safety to provide opportunities for prolonged
dosing and greater efficacy in the clinic. The Company is advancing its
pipeline to deliver the future of cancer care across a broad range of
haematological and solid cancer indications in areas of high unmet medical
need.

Find out more at www.bivictrix.com (http://www.bivictrix.com/)  and connect
with us on LinkedIn
(https://www.linkedin.com/company/bivictrix-therapeutics-plc/)  and
Twitter @BiVictriX (https://twitter.com/BiVictriX) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLLMFTMTJMBRI